Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for Senseonics Holdings, Inc. Common Stock and Orchestra BioMed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senseonics Holdings, Inc. Common Stock | 1 | 1 | 4 | 0 | 2.50 |
| Orchestra BioMed | 1 | 0 | 6 | 0 | 2.71 |
Senseonics Holdings, Inc. Common Stock presently has a consensus target price of $17.20, suggesting a potential upside of 97.47%. Orchestra BioMed has a consensus target price of $13.00, suggesting a potential upside of 112.42%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Senseonics Holdings, Inc. Common Stock.
Risk & Volatility
Valuation and Earnings
This table compares Senseonics Holdings, Inc. Common Stock and Orchestra BioMed”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senseonics Holdings, Inc. Common Stock | $35.26 million | 10.33 | -$69.11 million | ($2.23) | -3.91 |
| Orchestra BioMed | $33.48 million | 10.99 | -$52.70 million | ($0.85) | -7.20 |
Orchestra BioMed has lower revenue, but higher earnings than Senseonics Holdings, Inc. Common Stock. Orchestra BioMed is trading at a lower price-to-earnings ratio than Senseonics Holdings, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Senseonics Holdings, Inc. Common Stock and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senseonics Holdings, Inc. Common Stock | -225.09% | -165.80% | -80.14% |
| Orchestra BioMed | -184.60% | -149.61% | -54.15% |
Insider & Institutional Ownership
12.4% of Senseonics Holdings, Inc. Common Stock shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Orchestra BioMed beats Senseonics Holdings, Inc. Common Stock on 11 of the 14 factors compared between the two stocks.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
